Sickle Cell Disease
Sickle Cell Disease
Advertisement
Kristen Howell, PhD, MpHSickle Cell Disease | June 5, 2024
Kristen Howell, PhD, MPH, has investigated how transfer gaps in SCD care affect patients as they transition to adult care.
View More
Andrew MorenoSickle Cell Disease | May 22, 2024
The REACH trial’s findings suggest a reduced burden upon transfusion resources worldwide is possible.
Melissa BadamoSickle Cell Disease | May 8, 2024
The gene therapy, which costs $3.1 million, was approved by the FDA in December 2023.
Patrick DalySickle Cell Disease | May 2, 2024
Phase III data from the CLIMB SCD-121 trial verified the efficacy of exa-cel in eliminating vaso-occlusive crises in SCD.
Melissa BadamoSickle Cell Disease | May 2, 2024
Age, weight, graft failure, and donor type are some predictors of pain crisis after HSCT in patients with SCD.
Melissa BadamoSickle Cell Disease | April 26, 2024
In the one-year, fixed-dose extension period of the ESTIMATE study, mitapivat showed continued safety and efficacy in SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Patrick DalySickle Cell Disease | April 23, 2024
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Patrick DalySickle Cell Disease | April 19, 2024
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
Melissa BadamoSickle Cell Disease | April 18, 2024
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 12, 2024
Dr. Ansong-Ansongton shared what National Minority Health Month and Celebrate Diversity Month mean to him at ASPHO 2024.
Yaw Ansong-Ansongton, MDSickle Cell Disease | April 9, 2024
Dr. Ansong-Ansongton described data on the impact of abnormal mitochondrial retention and cold in red blood cells in SCD.
Zaina Inam, MDSickle Cell Disease | April 5, 2024
The study evaluated transplant outcomes in pediatric patients with SCD who had a history of red blood cell alloimmunization.
Patrick DalySickle Cell Disease | April 4, 2024
A standardized, local TCD supported by central quality review was implemented effectively in resource-constrained settings.
Melissa BadamoSickle Cell Disease | March 25, 2024
The two-year event-free survival was estimated to be 82.6%, and the two-year overall survival was 94.1%.
Patrick DalySickle Cell Disease | March 8, 2024
A new bill seeks to add a SCD health home model to state Medicaid programs to improve access and quality of treatment.
Patrick DalySickle Cell Disease | March 9, 2024
A myeloablative conditioning regimen containing thiotepa had promising efficacy and safety in patients with severe SCD.
Zahra Pakbaz, MDSickle Cell Disease | February 27, 2024
Dr. Pakbaz describes some of the difficulties faced by patients with SCD as they switch from pediatric to adult programs.
Patrick DalySickle Cell Disease | February 26, 2024
Reduction of hemolysis significantly predicted postinfusion transduction efficacy in patients with SCD treated with lovo-cel.
Melissa BadamoSickle Cell Disease | February 22, 2024
Exa-cel eliminated RBC transfusions in patients with transfusion-dependent β-thalassemia.
Advertisement
Advertisement
Advertisement
Latest News

July 16, 2024